

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Thiamazole

June 24, 2025

Therapeutic category

Thyroid and para-thyroid hormone preparations

Non-proprietary name

Thiamazole

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current	Revision
11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions (N/A)	11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions <u>Acute pancreatitis</u> <u>If symptoms such as upper abdominal pain, back pain, pyrexia, and</u> <u>vomiting or pancreatic enzyme abnormalities are observed,</u> <u>administration of this drug should be discontinued and appropriate</u> <u>measures should be taken.</u>

Note: The injectable dosage form of thiamazole is designated as a drug requiring preparation of a Drug Guide for Patients.

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.